PharmaShots

APRIL 25, 2023

In 2019, Mallinckrodt entered into a collaboration agreement with Silence Therapeutics to develop and commercialize RNAi therapeutics to treat life-threatening unmet diseases. Through the 2019 agreement, Mallinckrodt received the exclusive worldwide license to Silence’s SLN500. R&D Expenditure: $85.1M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Diabetes Packaging Immunity 40

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

Pharmacy Times

JULY 1, 2025

SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.

HIV Treatment and Prevention Agents 44

HIV Treatment and Prevention Agents Pharmacy Technician Insurance Coverage and Processing Specialty Pharmacies 44

RX Note

FEBRUARY 23, 2023

Soft Contact Lenses - A basic overview Red Eye - Discussion on few possible conditions Styes - Warm compresses are the mainstay of treatment Eye Floaters - It is not often treated, except in severe cases.

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58